PCSK9 and renal cell carcinoma: Unfortunately, due to the lower prevalence and distinct pathological characteristics of RCC, and the shorter duration of the PCSK9 inhibitor trials, there were few epidemiology studies focused on the association of PCSK9 inhibitors and RCC risk.